Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Opus Genetics (NASDAQ:IRD) in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $8.00 price objective on the stock. HC Wainwright also issued estimates for Opus Genetics’ Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.22) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.23) EPS.

Opus Genetics Price Performance

IRD opened at $1.06 on Wednesday. Opus Genetics has a 52-week low of $0.97 and a 52-week high of $3.40.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.01. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The business had revenue of $3.87 million for the quarter, compared to analysts’ expectations of $1.17 million. As a group, equities research analysts forecast that Opus Genetics will post -1.22 earnings per share for the current year.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.